Annual report pursuant to Section 13 and 15(d)

Acquisition (Tables)

v3.3.1.900
Acquisition (Tables)
 12 Months Ended
Dec. 31, 2015
Business Combinations [Abstract]  
Schedule of Consideration
The reconciliation of consideration given for the Acquired Property to the allocation of the purchase price for the assets and liabilities acquired based on their relative fair values is as follows:

Cash
 
$
8,000

Transition services obligation
 
500

Contingent consideration
 
4,476

   Total consideration
 
$
12,976

 
 
 
Thyroid
 
$
8,519

Pancreas
 
2,882

Biobank
 
1,575

Acquired intangible assets
 
$
12,976

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed
The reconciliation of consideration given for RedPath to the final allocation of the purchase price for the assets and liabilities acquired based on their relative fair values is as follows:
Cash
 
 
$
13,572

Subordinated note payable
 
 
7,517

   Cash
 
$
22,066

 
   Common stock
 
1,820

 
Contingent consideration
 
 
23,886

     Total consideration
 
 
$
44,975

 
 
 
 
Goodwill
 
 
$
15,666

  Pancreas Test
 
$
16,141

 
  Barrett's Test
 
18,351

 
Acquired intangible assets
 
 
34,492

Current assets
 
 
5,465

Indemnification asset, long-term - DOJ settlement
 
 
2,500

Other long-term assets
 
 
366

Current liabilities
 
 
(4,809
)
DOJ settlement, long-term (indemnified by RedPath)
 
 
(2,500
)
Deferred income tax liability
 
 
(6,205
)
     Total acquired assets
 
 
$
44,975

Pro Forma Information
However, pro forma results are not necessarily indicative of the results that would have occurred if the acquisition had been consummated as of the dates indicated, nor are they necessarily indicative of future operating results. 

 
 
 
 
 
2014
Revenue
$
9,786

Net loss
$
24,299

Loss per share
$
(1.63
)